NL-OMON56384招募中3 期
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation - Study of MRTX849 vs Docetaxel in Pts With Advanced NSCLC KRAS G12C Mut.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologically or cytologically confirmed diagnosis of NSCLC with KRAS
- •G12C mutation.
- •Candidacy to receive treatment with docetaxel.
- •Crossover Inclusion Criteria
- •1. Evidence of RECIST 1.1 defined disease progressoin on docetaxel per BICR.
- •2. ECOG performance status 0 - 2.
排除标准
- •Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510).
- •Active brain metastases.
- •Crossover Exclusion Criteria:
- •1. Receipt of any other systemic anti-cancer therapy after last administration
- •of docetaxel on the study.
研究者
相似试验
进行中（未招募）
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-507263-19-00Mirati Therapeutics Inc.628
招募中
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-NLMirati Therapeutics, Inc.450
招募中
3 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationAdvanced Non-Small Cell Lung Cancer2023-507263-19-00Mirati Therapeutics Inc.557
进行中（未招募）
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-CZMirati Therapeutics, Inc.450
进行中（未招募）
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-IEMirati Therapeutics, Inc.450